Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Linch DC, Vaughan Hudson B, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan DW, Stevenson PA, Wood JK, MacLennan KA, Anderson L, Gregory WM, Vaughan Hudson G. Linch DC, et al. Among authors: milligan dw. Br J Cancer. 1996 Jul;74(2):318-22. doi: 10.1038/bjc.1996.360. Br J Cancer. 1996. PMID: 8688344 Free PMC article. Clinical Trial.
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial.
Khwaja A, Linch DC, Goldstone AH, Chopra R, Marcus RE, Wimperis JZ, Russell NH, Haynes AP, Milligan DW, Leyland MJ, et al. Khwaja A, et al. Among authors: milligan dw. Br J Haematol. 1992 Oct;82(2):317-23. doi: 10.1111/j.1365-2141.1992.tb06424.x. Br J Haematol. 1992. PMID: 1419813 Clinical Trial.
G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial.
Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ, Smith GM, Hutchinson RM, Goldstone AH, Fielding AK, Vaughan Hudson G. Linch DC, et al. Among authors: milligan dw. Br J Haematol. 1997 Dec;99(4):933-8. doi: 10.1046/j.1365-2141.1997.4703274.x. Br J Haematol. 1997. PMID: 9432046 Free article. Clinical Trial.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S. Kottaridis PD, et al. Among authors: milligan dw. Cytotherapy. 2001;3(3):197-201. doi: 10.1080/146532401753174025. Cytotherapy. 2001. PMID: 12171726 Clinical Trial.
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. Thomson KJ, et al. J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606089 Clinical Trial.
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Morgan GJ, et al. Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4. Haematologica. 2012. PMID: 22058209 Free PMC article. Clinical Trial.
196 results